Alliance for Pandemic Preparedness

May 18, 2020

IgA MAb Blocks SARS-CoV-2 Spike-ACE2 Interaction Providing Mucosal Immunity

Category:

Topic:

  • Ejemel et al. identified a cross-reactive human IgA monoclonal antibody (MAb362) than can bind to both SARS-CoV and SARS-CoV-2 spike proteins and competitively block hACE2 receptor binding. It also neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. MAb362 IgA may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine. 

Ejemel et al. (May 15, 2020). IgA MAb Blocks SARS-CoV-2 Spike-ACE2 Interaction Providing Mucosal Immunity. Pre-print downloaded May 18 from https://doi.org/10.1101/2020.05.15.096719